BioCentury
ARTICLE | Clinical News

Windtree completes enrollment in Phase IIb of Aerosurf to treat RDS in premature infants

June 9, 2017 7:52 PM UTC

Windtree Therapeutics Inc. (OTCQB:WINT) completed enrollment of 221 premature infants 28-32 weeks of gestational age with respiratory distress syndrome (RDS) in a Phase IIb trial of Aerosurf lucinactant. The trial is comparing up to 2 repeat doses of 25 or 50 minutes aerosolized Aerosurf plus nasal continuous positive airway pressure (nCPAP) vs. nCPAP alone.

The blinded, international trial is evaluating time to respiratory failure or death due to RDS as its primary endpoint. Top-line data from the trial are expected in July...

BCIQ Company Profiles

Windtree Therapeutics Inc.